DHT (dihydrotestosterone) is a hormone derived from testosterone that binds to hair follicle receptors and causes them to shrink over time. In an inflamed scalp, follicles become hypersensitive to DHT even at normal hormone levels, accelerating this miniaturisation process.
Dihydrotestosterone (DHT) is a potent androgen hormone derived from testosterone by the enzyme 5-alpha reductase. In genetically susceptible hair follicles, DHT binds to androgen receptors and progressively shrinks the follicle over successive hair cycles — a process called miniaturisation. The follicle produces progressively thinner, shorter hair until it eventually becomes dormant.
The mechanism has three stages:
This is the critical insight most hair loss coverage misses: DHT sensitivity, not DHT level, determines impact.
Scalp inflammation increases the sensitivity of follicle androgen receptors to DHT. An inflamed follicle can be devastated by a DHT level that would be harmless in a healthy scalp environment. This is why many women with normal hormone blood tests still experience significant hair loss — their follicles are inflamed and hyper-reactive.
DHT blockers (like finasteride) work by reducing DHT levels. But if the follicle is inflamed, even reduced DHT can still cause miniaturisation. This is why DHT-blocking approaches often underperform for women with inflammatory hair loss.
Men have far more testosterone (and therefore more DHT), which is why androgenetic alopecia is more pronounced and faster in men. In women, FPHL presents differently — diffuse thinning at the crown and widening part rather than the classic receding hairline.
Women's hair loss often involves lower absolute DHT levels but higher follicle sensitivity — frequently caused by the inflammation that accompanies oestrogen decline in perimenopause and menopause.
Rather than trying to block DHT (which has side effects and doesn't address sensitivity), addressing the scalp inflammation that drives sensitivity is an alternative strategy. Calming the inflammatory environment reduces the follicle's vulnerability to whatever DHT is present.
This is the mechanism ThriivX H3 targets: Kannopia-Active reduces scalp inflammation via the endocannabinoid system, making follicles less reactive to DHT without interfering with DHT levels systemically.
Instead of fighting DHT, ThriivX H3 targets the inflammation that makes follicles vulnerable to it.
Shop ThriivX H3 →Most supplements address nutrient deficiency. ThriivX H3 addresses scalp inflammation — the upstream trigger that's driving follicle miniaturization.
Get ThriivX H3 →Results vary. Consult your physician before starting any supplement.